Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics

References

• Korea Health Industry Development Institute. Pharmaceutical industry analysis report. Chungbuk: Korea Health Industry Development Institute; 2017.
   Google Scholar
• Korea Health Industry Development Institute. Pharmaceutical industry analysis report. Chungbuk: Korea Health Industry Development Institute; 2016.
   Google Scholar
• Korea Drug Research Association. Overview of Korean pharmaceutical industry 2019. [cited 2019 July]. Available from: http://www.kdra.or.kr/english/03web01.php
   Google Scholar
• Ministry of Health and Welfare. “2012 pharmaceutical industry competitiveness enhancement plan” announced in preparation for effectivation of KOR-US FTA, drug price reduction, etc. 2012.
   Google Scholar
• Son K-B. Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis. Health Econ Rev. 2018;8(1):31.
   PubMedGoogle Scholar
• Korea Health Industry Development Institute. Innovative pharmaceutical company performance. Chungbuk: Korea Health Industry Development Institute; 2016.
   Google Scholar
• Son K-B, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open. 2019;9(3):e026603.
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2011;1:141.
   PubMed Web of Science ®Google Scholar
• Shin S, Song H, Jang S, et al. Development of the outcome index of hyperlipidemia treatments (lipid lowering agents). Seoul: Health Insurance Review and Assessment Service; 2009.
   Google Scholar
• Kwon H-Y, Godman B. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. BMC Health Serv Res. 2016;16(1):130.
   PubMedGoogle Scholar
• Sakshaug S, Furu K, Karlstad Ø, et al. Switching statins in Norway after new reimbursement policy–a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476–481.
   PubMed Web of Science ®Google Scholar
• Usher‐Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62(3):480–484.
   PubMed Web of Science ®Google Scholar
• Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761–766.
   Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):475–484.
   PubMedGoogle Scholar
• Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PloS One. 2014;9(7):e102146.
   PubMed Web of Science ®Google Scholar
• García-Gil M, Blanch J, Comas-Cufí M, et al. Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: a retrospective study of primary care electronic medical records. J Clin Lipidol. 2016;10(1):134–142.
   PubMed Web of Science ®Google Scholar
• Svensson E, Nielsen RB, Hasvold P, et al. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clin Epidemiol. 2015;7:213–223.
   PubMed Web of Science ®Google Scholar
• Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan’s National Health Insurance Research Database. BMJ Open. 2017 May 17;7(5):e014150.
   PubMed Web of Science ®Google Scholar
• Hye-Jae L, Tae-Jin L. Impact of price control on drug expenditure and factors associated with the drug switch among statins: analysis of HIRA-NPS data [Impact of price control on drug expenditure and factors associated with the drug switch among statins: analysis of HIRA-NPS data]. Health Policy Manage (HPM). 2013 6;23(2):112–123.
   Google Scholar
• Dave CV, Hartzema A, Kesselheim AS. Prices of generic drugs associated with numbers of manufacturers. N Engl J Med. 2017;377(26):2597–2598.
   PubMed Web of Science ®Google Scholar
• Luo J, Seeger JD, Donneyong M, et al. Effect of generic competition on atorvastatin prescribing and patients’ out-of-pocket spending. JAMA Intern Med. 2016;176(9):1317–1323.
   PubMed Web of Science ®Google Scholar
• Porath D. Size and dynamics of order-of-entry effects in pharmaceutical markets. Int J Market Res. 2018;60(1):50–66.
   Web of Science ®Google Scholar
• Yang D-W, Kim H-L, Tae-Jin L. Trend in the market share of generic drugs after the first generic entry. Korean J Health Econ Policy. 2017;23(4):23–43.
   Google Scholar
• Son K-B, Lopert R, Gleeson D, et al. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States [journal article]. Global Health. 2018 Oct 24;14(1):101.
   PubMedGoogle Scholar
• Zhang W, Guh D, Sun H, et al. The impact of price-cap regulations on exit by generic pharmaceutical firms. Med Care. 2016;54(9):884–890.
   PubMed Web of Science ®Google Scholar
• Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016;17(8):1027–1040.
   PubMed Web of Science ®Google Scholar
• Lieberman MB, Montgomery DB. First‐mover advantages. Strategic Manage J. 1988;9(S1):41–58.
   Web of Science ®Google Scholar
• Lieberman MB, Montgomery DB. First‐mover (dis) advantages: retrospective and link with the resource‐based view. Strategic Manage J. 1998;19(12):1111–1125.
   Web of Science ®Google Scholar
• Bae E-Y. Role of health technology assessment in drug policies: Korea. Value Health Reg Issues. 2019;18:24–29.
   PubMedGoogle Scholar